Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder...
Agency Continues to Take Steps to Reduce New Cases of Opioid Use Disorder